Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Role of the Alpha 1-adrenergic Antagonist, Prazosin, in the Reduction of Craving and Relapse in Alcohol and Cocaine-dependent Individuals: a Double-blind, Randomized, Controlled Clinical Trial

NCT00240227 is registered in ClinicalTrials.gov with US Department of Veterans Affairs as lead sponsor.

NCT NCT00240227
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00240227 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Role of the Alpha 1-adrenergic Antagonist, Prazosin, in the Reduction of Craving and Relapse in Alcohol and Cocaine-dependent Individuals: a Double-blind, Randomized, Controlled Clinical Trial
Lead sponsor
US Department of Veterans Affairs
Phase
Not applicable
Overall status
Terminated
Start date
April 30, 2004
Completion date
January 31, 2009
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alcoholism, cocaine dependence